Armata Pharmaceuticals, Inc. Common Stock (ARMP) is a publicly traded Healthcare sector company. As of May 21, 2026, ARMP trades at $8.18 with a market cap of $279.00M and a P/E ratio of -1.71. ARMP moved -3.78% today. Year to date, ARMP is +27.87%; over the trailing twelve months it is +260.89%. Its 52-week range spans $0.90 to $16.34. Analyst consensus is buy with an average price target of $17.50. Rallies surfaces ARMP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Armata Gains FDA Fast Track for AP-SA02 with Rolling BLA, Targets H2 2026 Phase 3: Armata Pharmaceuticals secured Fast Track designation for AP-SA02, its IV multi-phage therapy treating MSSA and MRSA complicated bacteremia, granting rolling BLA review, frequent FDA engagement and Accelerated Approval eligibility. It is backed by positive Phase 1b/2a diSArm results and $26.2 million DoD funding and targets Phase 3 initiation in H2 2026.
| Metric | Value |
|---|---|
| Price | $8.18 |
| Market Cap | $279.00M |
| P/E Ratio | -1.71 |
| EPS | $-4.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $16.34 |
| 52-Week Low | $0.90 |
| Volume | 210 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.90M |
| Net Income | $-173.80M |
| Gross Margin | 0.00% |
2 analysts cover ARMP: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $17.50.